Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Hydrocortisone × Thoracic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 73 Lymphoid 73 Genitourinary 23 Myeloid 5 Gastrointestinal 5 Sarcoma 4 Endocrine 4 CNS 4 Classical hematology 3 Breast 3 Plasma cell 2 Other 2 Thoracic 1 Other neoplasm 1 Head & Neck 1 Gynecologic 1

Conditions

Lung Neoplasms 1 Exanthema 1

Interventions

Carboplatin 1160 Cisplatin 884 Pemetrexed 840 pembrolizumab 620 Paclitaxel 606 Docetaxel 536 Gemcitabine 426 Radiotherapy 388 Erlotinib Hydrochloride 381 Nivolumab 340 Bevacizumab 336 Etoposide 293 durvalumab 262 Drug Therapy 255 osimertinib 236 atezolizumab 224 Radiosurgery 192 Gefitinib 186 Vinorelbine 149 Magnetic Resonance Spectroscopy 129 Ipilimumab 127 130-nm albumin-bound paclitaxel 123 Cetuximab 110 Blood Specimen Collection 105 Topotecan 103 anlotinib 102 tislelizumab 101 Surgical Procedures, Operative 101 Cyclophosphamide 100 Specimen Handling 99

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00473083 2017-04-04

LUTRAERL

British Columbia Cancer Agency

Phase 2 Completed

150 enrolled 13 charts

Exanthema, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡